Rita Numerof

President @NAIconsulting. Helping businesses across healthcare define/implement strategies to win in dynamic markets.

[Rita Numerof @RitaNumerof]

Market-driven healthcare is the future. My new book out today-"Bringing Value to Healthcare" https://t.co/2tyWWZJTsM

[Rita Numerof @RitaNumerof]

Healthcare has reached another inflection point. We've spent decades making incremental adjustments, yet costs continue to rise and dissatisfaction continues to grow.

My latest: https://t.co/NOHCithlqg

[Rita Numerof @RitaNumerof]

The @WaysandMeansGOP hearing underscored growing frustration with rising healthcare costs and limited evidence of measurable value. Organizations that can demonstrate both clinical and economic value will be best positioned for the future. https://t.co/4Cq2xulD8A

[Rita Numerof @RitaNumerof]

The recent hearing on hospital prices sent a clear signal: bipartisan patience with the current HCD model is wearing thin. Rising costs, consolidation and weak value transparency are now central questions in D.C. Incremental reform is no longer enough. https://t.co/RxKM7lQAoS

[Rita Numerof @RitaNumerof]

Pharma companies that continue to rely on legacy R&D and commercialization approaches will find it increasingly difficult to achieve approval and access on terms that support sustainable value. https://t.co/FAtrG234r8

[Rita Numerof @RitaNumerof]

A $300B patent cliff is reshaping pharma competition, value and decision-making. As exclusivity expires, new value benchmarks compress pricing power and raise the bar for differentiation. Evidence must drive pricing, access and long-term viability.
https://t.co/UwBVrcp7ml

[Rita Numerof @RitaNumerof]

Big pharma cut 22,000+ jobs in 2025 as a $300B patent cliff looms. Periodic restructuring is not unusual, but the scale & simultaneity of these layoffs reveals a deeper industry shift and why evidence has become the central determinant of value.

Read more:https://t.co/nNTUwOSrSa

[Rita Numerof @RitaNumerof]

Vinay Prasad’s departure from the @US_FDA has renewed debate about balancing scientific rigor with timely patient access. This moment should not be viewed as a departure from scientific standards, but as an opportunity to refine them. https://t.co/dmQls2oNHb

[Rita Numerof @RitaNumerof]

.@Pharmacy_Times: The FDA’s move to expand RWE in clinical trials is an important step forward. Raising the evidentiary bar won’t stifle innovation—it ties price to value and helps ensure the U.S. continues to lead in both innovation and accountability. https://t.co/GoNUSNW5DP

[Rita Numerof @RitaNumerof]

AI is rapidly becoming embedded across the pharmaceutical industry, but until organizations become more disciplined about defining the questions they need answered, even the most sophisticated AI capabilities will underperform.

Read More: https://t.co/Qrt0HMfSY1

[Rita Numerof @RitaNumerof]

Cost pressure, access demands and accountability expectations are accelerating disruption across HCD and insurance. As 2026 approaches, shrinking fee-for-service viability and rising consumer expectations mean incremental adjustments will not be enough. https://t.co/LdwuB6GBvV

[Rita Numerof @RitaNumerof]

Policy pressure is reshaping the pharma landscape, and 2026 will require sharper evidence and clearer value communication to stay competitive. Our 2026 Global Pharma Outlook breaks down the key opportunities and challenges ahead.

Read more:
https://t.co/JhLwZmdijt

[Rita Numerof @RitaNumerof]

A 43-day shutdown over temporary ACA subsidies revealed the bigger issue: a system with misaligned incentives. Leaders need to shift from managing crises to designing a system anchored in accountability, competition and improving care at affordable prices. https://t.co/mjAn11832Y

[Rita Numerof @RitaNumerof]

Following @Pfizer & @AstraZeneca’s new deals with the Trump Admin, https://t.co/JL6EktDrcE marks a significant shift—elevating DTC pricing to a national priority and challenging pharma’s opaque model to restore a rational link between cost and value. https://t.co/i5KWP308q6

[Rita Numerof @RitaNumerof]

The number of osteoporosis bone fractures is expected to increase by 68% from 1.9 million (2018) to 3.2 million in 2040, impacting patient quality of life and healthcare costs. Ask your doctor about screenings and prevention.

@Amgen @bonehealthBHOF @HealthyWomen

[Rita Numerof @RitaNumerof]

Osteoporosis fractures send more postmenopausal women to the hospital than strokes or heart attacks alone. Talk with your doctor about steps to improve your bone health. #WorldOsteoporosisDay

@Amgen @bonehealthBHOF @HealthyWomen

[Rita Numerof @RitaNumerof]

@Pfizer and @AstraZeneca’s new deals with the Trump Administration aren’t a one-time concession—they mark a structural reset. Facing 100% tariffs, both agreed to cut prices and expand U.S. investment, tying affordability to domestic production.

Read more:https://t.co/QN05Yy6zcz

[Rita Numerof @RitaNumerof]

2 out of 3 women with postmenopausal osteoporosis at high risk for fracture are at risk of breaking a bone in their lifetime. Discuss preventative measures with your doctor. #WorldOsteoporosisDay

@Amgen @bonehealthBHOF @HealthyWomen

[Rita Numerof @RitaNumerof]

Every 20 seconds in the U.S., a woman aged 55 or older suffers a fracture – often the first visible sign of postmenopausal osteoporosis. Talk with your doctor about screening for bone fracture risk.

#WorldOsteoporosisDay

@Amgen @bonehealthBHOF @HealthyWomen

[Rita Numerof @RitaNumerof]

.@HHSGov is changing pharma ad rules amid concern that DTC ads distort the patient–doctor relationship. As drugs enter the market, patients need clear info and physician guidance, but time for discussion is getting harder to find.

Read more @Forbes. https://t.co/d0O4E3jqXZ

[Rita Numerof @RitaNumerof]

China’s biotech sector is surging—now leading in both clinical trials and new drug licensing. In my latest @Forbes column, I detail what’s driving this shift and why the U.S. must prioritize innovation over short-term cost-cutting to stay competitive.https://t.co/f9hDFsTkCA